Patents by Inventor Brian Pedgrift

Brian Pedgrift has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted benzoylamino-indan-2-carboxylic acids and related compounds
    Patent number: 8569535
    Abstract: The present invention relates to novel compounds of the formula Ia: in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity, and are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: October 29, 2013
    Assignee: Sanofi
    Inventors: Thomas Joseph Caulfield, Jennifer Williford Clemens, Robert S. Francis, Brian Scott Freed, Stanly John, Tieu-Binh Le, Brian Pedgrift, Antonio Daniel Ramos, Gerard Charles Rosse, Martin Smrcina, David Squire Thorpe, William Shelly Wire, Jianhong Zhao
  • Benzimidazoles
    Patent number: 8288425
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: October 16, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael L. Edwards, Paul J. Cox, Shelley Amendola, Stephanie D. Deprets, Timothy A. Gillespy, Christopher D. Edlin, Andrew D. Morley, Charles J. Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir N. Majid, John C. Reader, Lloyd J. Payne, Nawaz M. Khan, Michael Cherry
  • Pyrimidine hydrazide compounds as PGDS inhibitors
    Patent number: 8258130
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: September 4, 2012
    Assignee: Sanofi
    Inventors: Suzanne C Aldous, Michael W Fennie, John Z Jiang, Stanly John, Lan Mu, Brian Pedgrift, James R Pribish, Barbara S Rauckman, Jeffrey S Sabol, Grzegorz T Stoklosa, Sukanthini Thurairatnam, Christopher Loren Vandeusen
  • SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS
    Publication number: 20100113462
    Abstract: The present invention relates to novel compounds of the formula I: wherein in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.
    Type: Application
    Filed: November 30, 2009
    Publication date: May 6, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Thomas J. CAULFIELD, Jennifer Williford CLEMENS, Robert S. FRANCIS, Brian S. FREED, Stanly JOHN, Tieu-Binh LE, Brian PEDGRIFT, Antonio D. RAMOS, Gerard Charles ROSSE, Martin SMRCINA, David S. THORPE, William WIRE, Jianhong ZHAO
  • PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS
    Publication number: 20100048568
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: September 30, 2009
    Publication date: February 25, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Suzanne C. Aldous, Michael W. Fennie, John Z. Jiang, Stanly John, Lan Mu, Brian Pedgrift, James R. Pribish, Barbara Rauckman, Jeffrey S. Sabol, Grzegorz T. Stoklosa, Sukanthini Thurairatnam, Christopher L. Vandeusen
  • Pyrrolopyrimidines
    Patent number: 7259154
    Abstract: Compounds of the formula and N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: August 21, 2007
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Paul Joseph Cox, Tahir Nadeem Majid, Stephanie Daniele Deprets, Shelley Amendola, Iain McFarlane McLay, Christopher Edlin, David John Aldous, Brian Pedgrift, Frank Halley, Michael Edwards, Bernard Baudoin
  • Benzimidazoles
    Publication number: 20060014756
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Application
    Filed: January 4, 2005
    Publication date: January 19, 2006
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Michael Edwards, Paul Cox, Shelley Amendola, Stephanie Deprets, Timothy Gillespy, Christopher Edlin, Andrew Morley, Charles Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir Majid, John Reader, Lloyd Payne, Nawaz Khan, Michael Cherry
  • Azaindoles
    Publication number: 20050267304
    Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Application
    Filed: November 23, 2004
    Publication date: December 1, 2005
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Paul Cox, Tahir Majid, Justine Lai, Andrew Morley, Shelley Amendola, Stephanie Deprets, Christopher Edlin, Charles Gardner, Dorothea Kominos, Brian Pedgrift, Frank Halley, Timothy Gillespy, Michael Edwards, Francois Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel Bezard, Chantal Carrez
  • Benzimidazoles
    Patent number: 6897208
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: May 24, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael L. Edwards, Paul J. Cox, Shelley Amendola, Stephanie D. Deprets, Timothy A. Gillespy, Christopher D. Edlin, Andrew D. Morley, Charles J. Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir N. Majid, John C. Reader, Lloyd J. Payne, Nawaz M. Khan, Michael Cherry
  • Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
    Publication number: 20050009859
    Abstract: Compounds of the formula I are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.
    Type: Application
    Filed: July 3, 2003
    Publication date: January 13, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Tahir Majid, Corey Hopkins, Brian Pedgrift, Nicola Collar, Friederike Wirtz-Brugger, Jean Merrill
  • Pyrrolopyrimidines
    Publication number: 20040142947
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: December 23, 2003
    Publication date: July 22, 2004
    Applicant: Aventis Pharmaceuticals, Inc.
    Inventors: Paul Joseph Cox, Tahir Nadeem Majid, Stephanie Daniele Deprets, Shelley Amendola, Iain McFarlane McLay, Christopher Edlin, David John Aldous, Brian Pedgrift, Frank Halley, Michael Edwards, Bernard Baudoin
  • Benzimidazoles
    Publication number: 20040048868
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) 1
    Type: Application
    Filed: October 24, 2002
    Publication date: March 11, 2004
    Inventors: Michael L. Edwards, Paul J. Cox, Shelley Amendola, Stephanie D. Deprets, Timothy A. Gillespy, Christopher D. Edlin, Andrew D. Morley, Charles J. Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir N. Majid, John C. Reader, Lloyd J. Payne, Nawaz M. Khan, Michael Cherry